Company Overview and News
2018-10-04 zacks - 1
Community Health Systems, Inc. (CYH - Free Report) recently announced that it has completed its pending divestiture of the 238-bed AllianceHealth Deaconess hospital in Oklahoma City, OK and its related businesses to a unit of INTEGRIS Health. The sale also consists of physician clinic operations and outpatient services. The effective date of the transaction is Oct 1, 2018. The company’s affiliates continue to operate seven hospitals in Oklahoma.
LMT CYH MOH RNVAZ RNVA WCG CYHHZ ANTM UTX RNVAW
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $4.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CYH CSBR CYHHZ
Credit rating giant Moody's Investors Service ("Moody's") recently downgraded the Corporate Family Rating (CFR) of Community Health Systems, Inc. (CYH - Free Report) from Caa2 to Caa3 and the Probability of Default Rating from Caa2-PD to Caa3-PD. The agency has further downgraded the first lien senior secured debt to Caa1 from B3, the junior lien debt to Ca from Caa3, the unsecured debt to C from Ca and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3.
CYH MOH CBT WCG CYHHZ ANTM RPM
Community Health Systems, Inc. (CYH - Free Report) subsidiary Health Management Associates (HMA) will pay more than $260 million to settle whistleblower lawsuits alleging wide-ranging misconduct in emergency rooms. This includes $62.5 million to settle allegations that HMA forced physicians to make unnecessary admissions to its hospitals.
CYH NBL LPNT MEDP CYHHZ
2018-09-26 sec.gov - 5
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-09-25 channelnewsasia - 2
REUTERS: A hospital operator now owned by Community Health Systems Inc will pay more than US$260 million to resolve claims it defrauded government health care programs and paid doctors kickbacks for patient referrals, the U.S. Justice Department said on Tuesday.
(Reuters) - A hospital operator now owned by Community Health Systems Inc will pay more than $260 million to resolve claims it defrauded government health care programs and paid doctors kickbacks for patient referrals, the U.S. Justice Department said on Tuesday.
HYG was up 74 bps on the last week compared to significant value loss in a week before.
LifePoint Health Inc. (LPNT - Free Report) has high exposure to Hurricane Florence, with 30% of its beds in North and South Carolina, which is within the forecast path of the storm, as per analysts as pointed out in CNBC news. This makes the stock vulnerable to earnings miss in the third quarter. Other companies to face the wrath include Community Health Systems, Inc. (CYH - Free Report) , HCA Healthcare, Inc.
CYH LPNT CYHHZ ENPH OXY THC
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CYH HDS CYHHZ
WEST PALM BEACH, Fla, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW), (“Rennova” or the “Company”) a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that acquired its second rural hospital in Tennessee on June 1, 2018, reports financial results for the three and six months ended June 30, 2018 and provides a business update.
CYH RNVAZ RNVA CYHHZ RNVAW
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CYH / Community Health Systems, Inc. on message board site Silicon Investor.
as of ET